Autolus Therapeutics plc (AUTL): Cash & Equivalents
$104.13M
As of 2025-12-31
$171.41M
As of 2026-06-30
-35.2%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $104.13M | -54.2% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $227.38M | -5.1% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $239.57M | n/a | 2025-03-20, Balance as of period end |
| 2023-09-30 | $256.42M | n/a | 2024-03-21, Balance as of period end |
| 2023-06-30 | $307.50M | n/a | 2024-03-21, Balance as of period end |
| 2023-03-31 | $343.03M | n/a | 2024-03-21, Balance as of period end |
| 2022-12-31 | $382.44M | n/a | 2024-03-21, Balance as of period end |
| 2022-09-30 | $163.05M | n/a | 2024-03-21, Balance as of period end |
| 2022-06-30 | $216.44M | n/a | 2024-03-21, Balance as of period end |
| 2022-03-31 | $268.56M | n/a | 2024-03-21, Balance as of period end |
| 2021-12-31 | $310.34M | n/a | 2024-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $104.13M | -54.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $743.29M | +25.1% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗